Oncolytics Biotech Inc. believes in a transparent and forward-facing approach to business.
Board of Directors Mandate
Audit Committee Mandate
Compensation Committee Mandate
Corporate Governance Committee Mandate
Science and Technology Committee Mandate
Code of Ethics for CEO, CFO and Accounting Officers
Employee Code of Ethics
Corporate Trading Policy
Policy on Trading and Confidential Information
Policy Regarding Accounting and Auditing Matters
Oncolytics Biotech® to Present REOLYSIN® Safety Data in combination with chemotherapy at ESMO 2017 Congress
Oncolytics® Biotech Inc. Appoints Andrew de Guttadauro, President of Oncolytics Biotech (U.S.) Inc.
Oncolytics Biotech® Inc. Opens U.S. Based Office in San Diego
Oncolytics Biotech® to Present REOLYSIN® Safety Data in combination with chemotherapy at ESMO 2017 Congress Read More
Oncolytics® Biotech Inc. Appoints Andrew de Guttadauro, President of Oncolytics Biotech (U.S.) Inc. Read More
Exploring REOLYSIN®’s Objective Response Rate in Females with Colorectal Cancer Read More
Oncolytics President and CEO Dr. Matt Coffey featured on @wallstanalyzer.
Listen to the interview here https://t.co/jyXO09gYRb. #TSX $ONC
Zacks Analyst @vanjohn10 talks #capital and valuation in #biotech—hear what he has to say about $ONC at 4:35. https://t.co/rxkFQSACBc